Maria Antonietta Aloe Spiriti

Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients

Giuseppe Visani, Carlo Finelli, U. Castelli et al. · British Journal of Haematology · 1990 · 193 citations

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial

Esther Natalie Olíva, Caterina Alati, Valeria Santini et al. · The Lancet Haematology · 2017 · 159 citations · Full text

Eltrombopag Versus Placebo, Thrombosis, Thrombopoiesis +7

A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS

Pierre Fenaux, Valeria Santini, Maria Antonietta Aloe Spiriti et al. · Leukemia · 2018 · 159 citations · Full text

Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional Database

Maria Teresa Voso, Susanna Fenu, Roberto Latagliata et al. · Journal of Clinical Oncology · 2013 · 136 citations · Full text

Therapy-related myelodysplastic syndrome–acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem

Roberto Latagliata, Maria Concetta Petti, Susanna Fenu et al. · Blood · 2002 · 122 citations · Full text